Beyond The FOB: Considerations For Development Of Drugs With Neurologic Side Effects

Discover the unique challenges of developing neuro-active drugs and how to overcome them in preclinical studies. Unlike traditional methods that rely heavily on clinical pathology and histology to determine maximum tolerated doses (MTDs) and disease progression, neuro-active drugs often require a focus on clinical signs that emerge during the in-life phase of drug development. These unique neurologic effects and side effects present specific hurdles for toxicologists, emphasizing the importance of species selection, neurological exams, and thoughtful clinical data collection.

In this presentation by G. Alex Wakefield, DVM, Vice President of Pharmacology and Veterinary Resources at Altasciences, you’ll gain valuable insights into managing toxicology programs for neuro-active drugs. Learn about the critical role of species selection and neurological exams, strategies to address development challenges posed by neurologic effects, the importance of clinical signs in better defining neurological drugs, and how careful clinical data collection can reduce the need for highly complex tools in preclinical research.